Objective: To establish and externally validate nomograms to predict the risk of postoperative complications after cytoreductive surgery for advanced epithelial ovarian cancer (AEOC) patients. Design: A retrospective cohort study. Setting: Multicenter Population or Sample: Patients with FIGO stage IIIC-IV epithelial ovarian cancer who underwent cytoreductive surgery. Methods: Patient preoperative characteristics were used to predict the risk of postoperative complications by univariate and multivariate analyses. Nomograms were developed based on multivariate modeling. Main Outcome Measures: Postoperative overall and severe complications. Results: Overall, 585 AEOC patients were included for analysis (training cohort = 426, validation cohort = 159). Among the clinical variables assessed, modified frailty index (mFI) (OR 1.96 and 2.18), FIGO stage (OR 2.31 and 3.22), and Surgical Complexity Score (SCS) (OR 1.16 and 1.23) were most strongly associated with the risk of overall and severe complications, respectively. The final nomograms had superior internal discrimination with the C-index were 0.74 and 0.78 for predicting overall and severe complications, respectively, as well as good consistency and stable calibration. Additionally, the validation cohort suggested a good external discrimination with the C-index were 0.92 and 0.91 to predict overall and severe complications, respectively. Conclusions: These two nomograms can help clinicians to predict the risk of postoperative complications, and instruct clinical decision-making, as well as perioperative care to prevent adverse outcomes for AEOC patients. Funding: The Department of Science and Technology of Sichuan Province (grant number 21PJ050). Keywords: Advanced epithelial ovarian cancer, Postoperative complications, Cytoreductive surgery, Nomogram

High-risk human papillomavirus (hrHPV) is the major cause of cervical cancer. The majority of hrHPV infections resolve spontaneously. However, when hrHPV escapes host’s immune system and establishes persistent infection in basal keratinocytes, self-clearance of the infection becomes exactly difficult, and medical intervention is urgently needed to eradicate viral infection and prevent cervical cancer. This review aimed to summarize our findings and achievements on REBACIN®—an anti-viral biologic with low cost, no cold chain and no hospitalization, and demonstrated that REBACIN® exhibits potent efficacy in clearing persistent hrHPV infections, promotes regression of associated lesions via targeted inhibition of viral E6/E7 oncogenes.